Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CXCR5 | P32302 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309925 | 0.82 | NPC1 (0.50) | SMN1; SMN2ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL1560542 | 0.74 | CXCR5 (0.61) | CXCR5 | |
| SCHEMBL3308995 | 0.73 | CXCR5 (0.64) | CXCR5 | |
| SCHEMBL29384020 | 0.72 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL659603 | 0.72 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL27775148 | 0.72 | CXCR5 (0.60) | CXCR5HSD17B10MAPT | |
| SCHEMBL18530688 | 0.72 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL18530692 | 0.72 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL6084148 | 0.71 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL1147223 | 0.70 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679346-B | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI-AVENTIS (FR) | 2014-10-22 | — | — | CN | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| CN-101679346-A | substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI AVENTIS | 2010-03-24 | — | — | CN | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | SMN1; SMN2 3325/4885CXCR5 1/4885ALDH1A1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.